心肌病遗传学的临床与机制见解
基因检测可按分子病因精确分组患者并识别无症状高危个体,新基因组技术有望推动突变特异性精准治疗。
要点
- 已鉴定出逾千种突变,涉及多种基因和通路,导致肥厚型、扩张型、限制型和致心律失常性心肌病。
- 基因检测可将患者按分子病因精确分组,并识别无疾病证据但高危的个体。
- 新基因组技术和分析策略有望揭示突变特异性病理生理并推动精准治疗。
核心结论
- 基因研究进展已定义心肌病的分子病因,基因检测可按分子病因精确分组患者并识别无症状高危个体,新基因组技术有望推动突变特异性精准治疗。
主要发现
- 已鉴定出逾千种突变,涉及多种基因和通路,导致肥厚型、扩张型、限制型和致心律失常性心肌病。
- 基因检测可将患者按分子病因精确分组,并识别无疾病证据但高危的个体。
- 新基因组技术和分析策略为全面探索心肌病遗传结构提供了机会。
临床怎么用
- 基因检测可按分子病因精确分组患者,并识别无疾病证据但高危的个体。
局限性
- 原文指出这些努力仍不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last quarter-century, there has been tremendous progress in genetics research that has defined molecular causes for cardiomyopathies. More than a thousand mutations have been identified in many genes with varying ontologies, therein indicating the diverse molecules and pathways that cause hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathies. Translation of this research to the clinic via genetic testing can precisely group affected patients according to molecular etiology, and identify individuals without evidence of disease who are at high risk for developing cardiomyopathy. These advances provide insights into the earliest manifestations of cardiomyopathy and help to define the molecular pathophysiological basis for cardiac remodeling. Although these efforts remain incomplete, new genomic technologies and analytic strategies provide unparalleled opportunities to fully explore the genetic architecture of cardiomyopathies. Such data hold the promise that mutation-specific pathophysiology will uncover novel therapeutic targets, and herald the beginning of precision therapy for cardiomyopathy patients.
引用
- Burke MA, Cook SA, Seidman JG, et al. Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy. J Am Coll Cardiol. 2016. PMID: 28007147. doi:10.1016/j.jacc.2016.08.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。